ELI LILLY & Co

LLY | NYSE | CIK: 0000059478 | SIC: 2834 Pharmaceutical Preparations | active
Indianapolis, Indiana | Founded: 1876
Eli Lilly and Company, incorporated in 1901 in Indiana, discovers, develops, manufactures, and markets human pharmaceutical products worldwide. Operating in a single business segment, Lilly sells products in approximately 90 countries across therapeutic areas including cardiometabolic health (Mounjaro, Zepbound, Jardiance, Humalog), oncology (Verzenio, Cyramza, Retevmo, Jaypirca), immunology (Ebglyss, Olumiant), and neuroscience. The company manufactures and distributes through facilities in the U.S., Puerto Rico, Europe, and Asia.
cardiometabolic-healthoncologyimmunologyneuroscienceunited-stateseuropeasiachina
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/LLY
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
MounjaroserviceGIP and GLP-1 receptor agonist for treatment of adults with type 2 diabetes.
ZepboundserviceFor treatment of adults with obesity or overweight and moderate to severe obstructive sleep apnea.
JardianceserviceFor treatment of type 2 diabetes, cardiovascular disease risk reduction, and chronic kidney disease.
HumalogserviceHuman insulin analog for treatment of diabetes.
HumulinserviceHuman insulins of recombinant DNA origin for treatment of diabetes.
BasaglarserviceLong-acting human insulin analog for treatment of diabetes, in collaboration with Boehringer Ingelheim.
TrulicityserviceFor treatment of type 2 diabetes in adults and pediatric patients and cardiovascular risk reduction.
VerzenioserviceFor treatment of HR+, HER2- metastatic and early breast cancer.
CyramzaserviceFor treatment of multiple advanced or metastatic cancers including gastric, NSCLC, colorectal, and hepatocellular.
ErbituxserviceFor treatment of certain colorectal and head and neck cancers.

Partnerships

PartnerTypeDescription
Boehringer IngelheimdevelopmentCollaboration on Basaglar (insulin analog) and Jardiance (type 2 diabetes and cardiovascular).
Innovent Biologics, Inc.developmentCollaboration on Tyvyt for multiple oncology indications in China.
Incyte CorporationdevelopmentCollaboration on Olumiant for rheumatoid arthritis, atopic dermatitis, and alopecia areata.
Almirall S.A.developmentCollaboration on Ebglyss for atopic dermatitis in Europe.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/LLY/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub